The role of high-dose myeloablative chemotherapy with haematopoietic stem cell transplantation (HSCT) in children with central nervous system (CNS) tumours

Main, Caroline; Wilson, Jayne S; Stevens, Simon P; Houlton, Aimee E; English, Martin; Kearns, Pamela R; Phillips, Bob; Pizer, Barry; Wilne, Sophie; Wheatley, Keith

DOI: 10.1186/s13643-015-0155-7

License: Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal
The role of high-dose myeloablative chemotherapy with haematopoietic stem cell transplantation (HSCT) in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis

Caroline Main 1*, Jayne S. Wilson 1, Simon P. Stevens 1, Aimee E. Houlton 1, Martin English 2, Pamela R. Kearns 1, Bob Phillips 3, Barry Pizer 4, Sophie Wilne 5 and Keith Wheatley 1

Abstract

Objectives: The objective of the study is to conduct a systematic review to compare the effects of high-dose chemotherapy (HDCT) with autologous haematopoietic stem cell transplantation (HSCT) versus standard-dose chemotherapy (SDCT) in children with malignant central nervous system (CNS) tumours.

Methods: Standard systematic review methods aimed at minimising bias will be employed for study identification, selection and data extraction. Ten electronic databases will be searched, along with citation searching and reference checking. Studies assessing the effects of HDCT with HSCT in children with CNS tumours will be included. The outcomes are survival (overall, progression-free, event-free, disease-free), response rates, short- and long-term adverse events and health-related quality of life (HRQoL). Two reviewers will independently screen and select randomised and non-randomised controlled trials and controlled and uncontrolled observational studies for inclusion. Quality assessment will be tailored to the different study designs. Where possible data will be summarised using combined estimates of effect for the hazard ratio for survival outcomes and the risk ratio for response rates. A fixed effect model will be used; sub-group analyses and meta-regression will be used to explore potential sources of heterogeneity between studies.

Discussion: Given the poor prognosis of malignant brain tumours in children in terms of survival and quality of life, this review will help guide clinical practice by summarising the current evidence on the use of high-dose myeloablative chemotherapy with stem cell support in children with CNS tumours.

Keywords: Children, Central nervous system tumours, High-dose chemotherapy, Haematopoietic stem cell transplantation, Systematic review
Background

Tumours of the central nervous system (CNS) represent a diverse group of neoplasms that account for approximately 25% of all childhood cancers. They are the leading cause of cancer-related death in childhood and severe morbidity in survivors. High-grade gliomas (HGG) [glioblastoma multiforme (GBM) and anaplastic astrocytomas (AA)], diffuse intrinsic pontine gliomas (DIPG), primitive neuroectodermal tumours (PNETs, including medulloblastoma) and ependymoma constitute the majority of these malignant tumour types. To date, multimodal treatment involving surgery, radiotherapy and chemotherapy has formed the mainstay of treatment for CNS tumours. However, the survival rate remains poor in some high-risk histological tumour types and for patients with residual, recurrent or disseminated disease. Therapeutic options in most of these patients are limited by previous chemotherapy and radiotherapy and the need to limit re-irradiation in second-line treatment due to the deleterious effects on the developing brain and spinal cord.

High-dose chemotherapy (HDCT) followed by haematopoietic stem cell transplantation (HSCT) has been used as frontline as well as salvage therapy in children with a variety of CNS malignancies [1–3]. This strategy is based on the principle of high-dose therapy facilitating better penetration of the blood-brain barrier (BBB) and an increase in the dose-response curve to chemotherapeutic compounds. Clinically, however, severe myelosuppression limits dose escalation unless the haematopoietic stem cell transplantation is rescued shortly after infusion. The use of HDCT followed by HSCT has proven to be feasible and a number of single arm phase II trials have assessed the effects of HDCT with HSCT in different groups of children with CNS tumours. These have included infants [4,5] and children with newly diagnosed [6] or relapsed medulloblastoma [7,8], HGG [9–12] and relapsed or progressive ependymoma [13]. The totality of the evidence related to using HDCT with HSCT in children with CNS tumours has however not been systematically assessed. This review therefore aims to assess the effects of HDCT with HSCT versus SDCT in children with malignant CNS tumours.

Methods

Standard systematic review methodology aimed at minimising bias will be employed, and reporting will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [14]. The protocol for this review is registered with PROSPERO (CRD42015020402). Available from http://www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42015020402.

Data sources and searches

This review forms part of a wider work programme of systematic reviews which aim to assess the effects of different interventions for the treatment of CNS tumours in children, adolescents and young adults. Searches have therefore been conducted for studies examining the effects of surgery, radiotherapy, chemotherapy, immunotherapy, hormone therapy, biological therapies and imaging used alone or as part of a multi-modality treatment regimen for all types of paediatric brain tumours. No study design filters have been applied to the searches. Specific details of the searches conducted are detailed below.

Bibliographic databases: A comprehensive, broad search strategy was developed using a combination of medical subject headings (MeSH) and free text terms. The searches were limited by date from 1985 to November week 1, 2014. No language or publication status restrictions were applied, and ongoing studies were included.

The searches for published studies were undertaken using the following databases: MEDLINE (OvidSP); MEDLINE In-Process Citations and Daily Update (OvidSP); EMBASE (OvidSP); Cochrane Database of Systematic Reviews (CDSR) (Wiley); Cochrane Central Register of Controlled Trials (CENTRAL) (Wiley); CINAHL Plus (EBSCO); Database of reviews of effects [DARE (Centre for Reviews and Dissemination (CRD) website)] and Health Technology Assessment (HTA) (CRD website). The search strategy used for the MEDLINE search is reported in Appendix 1.

Grey literature, completed and on-going studies were identified by searches of NIH Clinical Trials (http://www.clinicaltrials.gov/); Current Controlled Trials (http://www.controlled-trials.com/) and WHO International Clinical Trials Registry Platform (ICTRP) (http://www.who.int/ictrp/en/).

Other sources: Experts in the field, from both the Project Advisory and Patient and Public Involvement (PPI) Groups were contacted with a list of identified studies to find out whether they had knowledge of any further studies that had not been retrieved by the electronic searches. Reference lists of all studies included in the present review will be checked and citation searching undertaken in order to identify any further studies not retrieved by the electronic searches.

All identified references were downloaded into Endnote X7 software for further initial assessment and handling. As a preliminary first stage to the broader set of reviews, inclusion screening on the basis of the population and broader set of applicable interventions was undertaken, with all included studies being ‘mapped’ by study design. Where flexibility is needed throughout the work programme for reference management and handling, Endnote software will be linked to bespoke Access databases in order facilitate sorting and manipulation of data items within indexed fields and abstracts.
Inclusion/exclusion criteria

Population
Infants, children and young adults (up to age 25 years) with diagnoses of any type of malignant CNS tumour. These include but are not limited to high- and low-grade gliomas (HGG and LGG), diffuse intrinsic pontine glioma (DIPG), medulloblastoma, ependymoma, germ cell tumours, atypical teratoid rhabdoid tumour (AT/RT), primitive neuroectodermal tumours and pineoblastoma. Studies that include both children and adults within the relevant populations will be included provided results are reported separately for children (defined as up to the age of 25). Likewise, studies conducted in children with different tumour types (e.g. solid tumours) will also be included provided results are reported separately for CNS tumours.

Interventions
HDCT with HSCT. High-dose methotrexate will be excluded as the term high-dose is used in the context of needing supportive care with folinic acid rescue as opposed to conventional standard dose methotrexate.

Comparator (for controlled studies): Standard or dose intensive chemotherapy.

Outcomes
Overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), event-free survival (EFS), response rates, short- and long-term adverse events and health-related quality of life (HRQoL). Response status data prior to and after HDCT regimens need to be reported where either multi-modal therapy regimens are being assessed or studies include populations with different types of tumours within the same study. Studies which do not report both baseline and post-HDCT response data will be excluded.

Study designs
Randomised controlled trials (RCTs), non-randomised comparative studies, single arm phase II trials, cohort studies, case-control studies and case series (both prospective and retrospective) will be included provided that ten or more participants have been included in studies that have assessed single tumour types and fifteen or more participants have been included in studies that have assessed ‘mixed’ CNS tumour types within the same study. Cross-sectional studies and multiple and single case reports will be excluded.

Study selection
Study selection will be undertaken in two stages by two reviewers working independently. Titles and abstracts will be screened for inclusion/exclusion. Studies marked for inclusion by either reviewer will then undergo full independent text assessment. Any discrepancies will be resolved by recourse to the abstracts or full texts or through consensus with a third reviewer. A PRISMA flow chart illustrating the study selection process will be documented [14].

Data extraction
Data will be recorded on a standard data extraction form and entered onto a bespoke computer database developed in either Access or Excel. The data will be extracted by one reviewer and checked by a second for accuracy. Any discrepancies will be resolved by recourse to the abstracts or full texts. The method of randomisation will be documented. The flow chart illustrating the study selection process will be documented [14].

Assessment of risk of bias in studies
The quality of RCTs will be assessed using the eight criteria in the Cochrane Collaboration’s tool for assessing risk of bias, which covers random sequence generation and allocation concealment (selection bias); blinding ([participants, personnel and outcome assessors], performance and verification bias); completeness of outcome data (attrition bias); selective outcome reporting (reporting bias) and other sources of bias [15]. These criteria will be adapted for use with non-randomised comparative studies, with an assessment of baseline balance between groups being instigated instead of an assessment of the method of random sequence generation. For non-comparative studies, the six-point checklist developed by CRD, York for the assessment of observational studies will be utilised (https://www.york.ac.uk/crd/guidance/) [16]. This checklist asks whether the sample is representative of the usual clinical population to whom the results will be extrapolated, whether the inclusion criteria are explicit and individuals entered the study at similar points in their disease progression (selection bias), whether follow-up was long enough for important outcomes to occur and whether outcomes were assessed using objective criteria or assessed blinded (detection bias). If a sub-series has
been undertaken, it also asks whether there was a sufficient description of the distribution of prognostic factors. As well as the risk of bias tool and CRD checklist, for all studies, there will be an assessment of the adequacy of the sample size, the use of concomitant treatments, treatment compliance, the use of objective outcomes and the timing of outcome assessments, the appropriateness of the statistical analysis and whether the author’s conclusions are justified and consistent with the results presented. External validity will also be assessed according to the ability of the reader to consider the applicability of the findings to a patient group in practice.

All assessment will be at the overall study level, not at the level of the individual outcomes. In addition to the methodological criteria listed above, the GRADE framework may be used to consider inconsistency between studies, precision of results, likelihood of publication bias and applicability of results to population(s) of interest [17]. Quality assessment will be undertaken by one reviewer independently and checked for accuracy by a second. Any disagreements will be resolved by recourse to the study paper(s), and a third reviewer will be consulted where necessary.

Data synthesis and analysis

Narrative synthesis

A narrative synthesis of study results will be presented (including text, figures and tables), to provide adequate interpretation of study findings. Studies will be grouped by tumour type, study design, intervention, and treatment line (induction, consolidation, salvage). The outcomes considered include overall survival, PFS, DFS, EFS, response rates, adverse events and HRQoL. Therefore, outcomes will be expressed in terms of hazard ratios [HR; (adjusted or unadjusted)] and risk ratios (RR). All analyses will be conducted per outcome, including all studies that have reported data for the outcome.

RCTs

Where more than one RCT has addressed the same question and they are considered to be clinically similar (based on patient population and study treatments), results will be combined in a standard pair-wise meta-analysis using assumption free methods. All analyses will be carried out on an ITT basis where possible, using the HR or RR as appropriate. Heterogeneity of treatment effect, if present, will be investigated using the chi-squared test for heterogeneity and the I² statistic [18]. Further sub-group analyses, to explore differences between the trials in terms of patient baseline characteristics such as tumour grade, prior treatments (dose, number of cycles) will be undertaken as necessary to investigate whether the treatment effect differs between patient sub-groups.

If feasible and significant heterogeneity is identified, this will be investigated using meta-regression. The following pre-specified factors will be investigated: quality of the primary studies; tumour type; prior treatment regimens (RT versus no RT); induction/consolidation/salvage therapy; dose and number of treatment cycles. All analyses will be conducted using RevMan (version 5.1) and STATA (STATA™ for Windows, version 10.1, Stata Corp; College Station, TX).

Assessment of small study effects

For each meta-analysis containing ten or more studies, the likelihood of small study effects and publication bias, namely the tendency for smaller studies to provide more positive findings, will be investigated though the construction of funnel plots and statistical tests for small study effects (such as the Peters Test) [19].

Non-randomised comparisons

Differences in outcome between studies will be assessed by formal statistical (e.g. chi-squared tests to compare response rates) and if the data permit, appropriate tests for time-to-event and continuous parameters. Graphical displays will be constructed in order to allow informal comparison of the results between studies. Differences in baselines characteristics of the patients that might explain any apparent differences in outcome will be examined.

Where both RCTs and non-randomised studies have assessed similar interventions within the same tumour type, a comparison of the effect sizes between the two different study designs will be conducted to evaluate any differential treatment effects by study design.

Discussion

Although this methodology has been designed to be comprehensive and to minimise bias, we anticipate some limitations with this review. The evidence base is likely to be highly heterogeneous with different HDCT interventions evaluated as part of a multimodality treatment regimen. Furthermore, these will be assessed in different patient populations as induction, consolidation or salvage therapy. Additionally, the majority of the evidence will come from single-arm phase II trials and small case series both of which have a strong risk of bias. It is therefore likely that any conclusions that can be drawn from the review will be tentative with a lot of uncertainty. However, given the paucity of the available evidence in order to inform treatment decision making in terms of the risk-benefit profile of different types of HDCT in the treatment of children with CNS
tumours, it is very important to undertake this review.

To ensure that our findings have clinical impact on patients, their parents and the physicians who care for them, results will be disseminated broadly by presenting at scientific conferences, publishing in peer-reviewed journals, and through our established Patient and Public Involvement (PPI) partners who work for established high profile UK Brain Tumour Charities and our Clinical Steering Group. For completeness, a list of the individual’s and their affiliations involved in both of these groups is provided in Appendix 2.

Appendix 1: Clinical Effectiveness Search Strategy
Medline (OvidSP): 1985—October Week 4 2014
1. Glioma/ or Brain Neoplasms/ or Meningioma/ or Glioblastoma/ or Astrocytoma/
2. (brain or brainstem or intracranial or posterior fossa) adj3 (cancer* or carcinom* or tumour* or tumour* or neoplasm*).mp.
3. (Astrocytoma* or Brain Stem Glioma* or Medulloblastoma* or Primitive Neuroectodermal Tumo*r* or ganglioneuroblastoma* or CNS neuroblastoma* or Ependymoblastoma or Medulloepithelioma or Pineal Parenchymal Tumour* or (Atypical Teratoid adj1 tumo?r*) or Oligoastrocytoma* or ((Pilocytic or Gemistocytic) adj1 astrocytoma*) or ependymoma or primitive neuroectal tumo?r*).mp.
4. (((Diffuse fibrillary or Gemistocytic or Pilocytic Pilomyxoid Protoplasmic Subependymal giant cell) adj1 astrocytoma*) or Oligoastrocytoma or Oligodendroglioma or Oligoastrocytoma or Pleomorphic xanthoastrocytoma or ((astrocytoma or oligoastrocytoma or oligodendroglioma) adj1 astrocytoma*) or Glioblastoma or Gliomatosis cerebi or Gliosarcoma or ((diffuse intrinsic pontine glioma or low grade brain stem) adj1 glioma*) or (classic or desmoplastic or nodular or large cell or nodularity) adj1 medulloblastoma* or Primitive Neuroectodermal Tumo*r* or (ganglioneuroblastoma or neuroblastoma) adj1 central nervous system* or Ependymoblastoma or Pineoblastoma or pineal parenchymal tumo?r* or (central nervous system adj1 atypical teratoid) or (central nervous system adj1 rhabdoid tumo?r*) or Germinomas or ((immature or mature or malignant transformation) adj2 teratomas)).mp.
5. 1 or 2 or 3 or 4
6. exp Surgical Procedures, Operative/
7. surg*.mp.
8. debulk*.mp.
10. 6 or 7 or 8 or 9
11. (chemotherap* or antineoplastic agents or cytotoxic or alkylating agents or nitrosoureas or antimetabolite* or antitumor?r or (antibod* or monoclonal) adj3 Human*) or plant alkylid* or (hormone* adj 1 agent*) or antihormone* or (hormone* adj 1 hormone*) or (hormone* adj 1 system*) or systemic therap*).mp.
12. (Everolimus or Afinitor or Cetuximab or Erbitux or Bevacizumab or Avastin or Cediranib or Recentin or Lomustine or CCNU or CeeNU or Carmustine or BiCNU or Carustine or EthylNitrosourea or Streptozocin or Sorafenib or Nexavar or Tipilamib* or Zanemsta or Erlotinib or Tarceva or Sorafenib or Nexavar or Temsirolimus or Torisel or Sunitinib or Sutent or irinotecan or Camptosar or Campto or Vandetanib or Caprelsa or Cavozantinib or Cometrix or XL184 or Axitinib or AG013736 or Inlyta).mp.
13. 11 or 12
14. exp Immunotherapy/ae, cl, ct, mt, mo, nu, px, st
15. exp Genetic Therapy/ae, cl, ct, mt, mo, nu, ut
16. exp Imaging, Three-Dimensional/ or exp Whole Body Imaging/ or exp Magnetic Resonance Imaging/
17. exp Tomography, Emission-Computed/ or exp Four-Dimensional Computed Tomography/ or exp Tomography/ or exp Tomography, Emission-Computed, Single-Photon/ or exp Positron-Emission Tomography/
18. 16 or 17
19. (radiation therapy or radiotherap* or intensity modulat* radiotherapy* or radiosurgery or radiation oncology or reduced boost volume radiotherap* or hyperfractionat* stereotactic radiotherap* or adjuvant radiotherap* or body radiotherap* stereotactic* or computer assisted radiotherap* or computer assisted radiotherap* planning or conformal radiotherap* or dosage* radiotherap* or dose fractionation* radiotherap* or high energy radiotherap* or implant radiotherap* or intensity or modulated radiotherap* or interstitial radiotherap* or image guided radiotherap* or stereotactic guid* radiotherap* or local therap*).mp.
20. 10 or 13 or 14 or 15 or 18 or 19
21. 5 and 20
22. (Response or overall survival or progression* free survival or event* free survival or time to recurrence or time to progression or disease* free interval* or endocrinopath* or ((growth or thyroid) adj1 hormone adj3 deficienc*) or ((glucocorticoid or gonadotropin) adj3 deficienc*) or endocrine dysfuct* or (cardiac function* adj3 impair*) or ataxia or spastic paresis or visual dysfunc* or epilepsy or hemiparesis or neurolog* deficit*).mp.
23. 21 and 22
24. limit 23 to (year = ’1985-Current’ and (’newborn infant (birth to 1 month)’ or ‘infant (1 to 23 months)’ or ‘preschool child (2 to 5 years)’ or ‘child (6 to 12 years)’ or ‘adolescent (13 to 18 years)’ or ‘young adult (19 to 24 years)’) and humans)
Appendix 2

Table 1 List of members of the Clinical Steering Group

<table>
<thead>
<tr>
<th>Name</th>
<th>Speciality</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant Holding Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Martin English</td>
<td>Consultant paediatric oncologist</td>
<td>Birmingham Children's Hospital, Birmingham</td>
</tr>
<tr>
<td>Professor Pamela Kearns</td>
<td>Consultant paediatric oncologist</td>
<td>Birmingham Children's Hospital, Birmingham</td>
</tr>
<tr>
<td>Dr. Bob Phillips</td>
<td>Consultant paediatric oncologist</td>
<td>Leeds Children's Hospital, Leeds</td>
</tr>
<tr>
<td>Professor Barry Pizer</td>
<td>Consultant paediatric oncologist</td>
<td>Alder Hey Children’s Hospital, Liverpool</td>
</tr>
<tr>
<td>Dr. Sophie Wilne</td>
<td>Consultant paediatric oncologist</td>
<td>Nottingham University Hospital, Nottingham</td>
</tr>
<tr>
<td>Clinical Steering Group Members</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Darren Hargrave</td>
<td>Consultant paediatric oncologist</td>
<td>Great Ormond Street Hospital, London</td>
</tr>
<tr>
<td>Professor David Walker</td>
<td>Consultant paediatric oncologist</td>
<td>School of Human Development, University of Nottingham</td>
</tr>
<tr>
<td>Dr. Heidi Traunecker</td>
<td>Consultant paediatric oncologist</td>
<td>University Hospital of Wales, Cardiff</td>
</tr>
<tr>
<td>Dr. Nicky Thorp</td>
<td>Consultant oncologist</td>
<td>Clatterbridge Centre for Oncology, Flintshire</td>
</tr>
<tr>
<td>Professor Richard Grundy</td>
<td>Paediatric neuro-oncology and cancer biology</td>
<td>School of Medicine, University of Nottingham</td>
</tr>
<tr>
<td>Professor Roger Taylor</td>
<td>Professor of clinical oncology</td>
<td>College of Medicine, Swansea University</td>
</tr>
<tr>
<td>Professor Simon Bailey</td>
<td>Consultant paediatric oncologist</td>
<td>Great North Children’s Hospital, Newcastle</td>
</tr>
<tr>
<td>Dr. Conor Mallucci</td>
<td>Consultant paediatric neurosurgeon</td>
<td>Alder Hey Children’s Hospital, Liverpool</td>
</tr>
<tr>
<td>Dr. Susan Picton</td>
<td>Consultant paediatric oncologist</td>
<td>Leeds Children’s Hospital, Leeds</td>
</tr>
<tr>
<td>Dr. Alison Evans</td>
<td>Head of research and policy</td>
<td>The Brain Tumour Charity</td>
</tr>
<tr>
<td>Rosemary Wormington</td>
<td>Head of support</td>
<td>Brain Tumour Support</td>
</tr>
<tr>
<td>Sharon Sambrook</td>
<td>Support co-ordinator</td>
<td>Brain Tumour Support</td>
</tr>
</tbody>
</table>

Abbreviations
AA: anaplastic astrocytoma—a rare grade III tumour that develops from the neuroepithelial tissue; AT/RT: atypical teratoid rhabdoid tumour—an embryonal tumour that can occur anywhere in the central nervous system; BBB: blood-brain barrier—a highly selective permeable barrier that separates the circulating blood from the brain extracellular fluid in the central nervous system; CNS: central nervous system—the part of the nervous system consisting of the brain and the spinal cord; DIFG: diffuse intrinsic pontine glioma—heterogeneous group of tumours occurring in the brainstem and cervicomедullary junction that are typically anaplastic astrocytomas or glioblastoma multiforme; GBM: glioblastoma multiforme—also known as glioblastoma or grade IV astrocytoma. It involves the glial cells and develops from the neuroepithelial tissues; HDIC: high-dose chemotherapy—an intensive drug treatment to kill cancer cells, but that also destroys the bone marrow and can cause other severe side effects. High-dose chemotherapy is usually followed by bone marrow or stem cell transplantation to rebuild the bone marrow; HGG: high-grade glioma—high-grade gliomas encompass the WHO grade III gliomas (anaplastic astrocytoma) and grade IV gliomas (glioblastoma multiforme); HSCT: haematopoietic stem cell transplantation—the intravenous infusion of haematopoietic stem cells usually derived from bone marrow, peripheral blood or umbilical cord blood to re-establish haematopoietic function in patients whose bone marrow or immune system is damaged or defective; PNTE: primitive neuroectodermal tumours—a malignant neural crest tumour; SDCT: standard dose chemotherapy—chemotherapy delivered within standard dosing schedules without the use of haematopoietic stem cell transplantation.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
CM conceived and designed the study, wrote the protocol, and registered the review with the PROSPERO database. JSW conceived and designed the study and read and commented on the protocol. SPS designed the study and read and commented on the protocol. AEE designed the study and read and commented on the protocol. AEE provided statistical input and read and commented on the protocol. ME provided clinical input, conceived the study concept and read and commented on the protocol. PRK provided clinical input and read and commented on the protocol. RP provided clinical input, conceived the study concept and read and commented on the protocol. SW conceived and designed the study, conceived the study concept and read and commented on the protocol. KW conceived and designed the study, provided methodological and statistical input, read and commented on the protocol and is the guarantor of the review. All authors approved the final protocol. All authors read and approved the final manuscript.

Funding sources
The review is funded by the Research for Patient Benefit (RfPB) Programme, National Institute for Health Research (NIHR) grant number: PB-PG-1112-29122. The review is funded by the Research for Patient Benefit (RfPB) Programme, National Institute for Health Research (NIHR) grant number: PB-PG-1112-29122. The review is funded by the Research for Patient Benefit (RfPB) Programme, National Institute for Health Research (NIHR) grant number: PB-PG-1112-29122. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Author details
© Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. © Birmingham Children’s Hospital NHS Foundation Trust, Birmingham, UK. © Centre for Reviews and Dissemination (CRD), University of York, York, UK. © Alder Hey Children’s NHS Foundation Trust, Liverpool, UK. © Queen’s Medical Centre, Nottingham University Hospitals’ NHS Trust, Nottingham, UK.

Received: 31 July 2015 Accepted: 9 November 2015
Published online: 20 November 2015
References


